(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/283049 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/02* (2006.01)
A61K 31/00 (2006.01) *A61K 47/12* (2006.01)
A61K 39/00 (2006.01) *A61K 47/26* (2006.01)

(21) International Application Number:
PCT/US2022/034493

(22) International Filing Date:
22 June 2022 (22.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/220,006 09 July 2021 (09.07.2021) US

(71) Applicant: **MACROGENICS, INC.** [US/US]; 9704 Medical Center Drive, Rockville, Maryland 20850 (US).

(72) Inventors: **SAMPATHKUMAR, Krishnan**; c/o Marogenics, Inc, 9704 Medical Center Drive, Rockville, Maryland 20850 (US). **ZHOU, Yan**; c/o Macrogenics, Inc., 9704 Medical Center Drive, Rockville, Maryland 20850 (US). **BURKE, Stephen James**; c/o Macrogenics, Inc., 9704 Medical Center Drive, Rockville, Maryland 20850 (US).


(74) Agent: **SIMKIN, Michele M.** et al.; Foley & Lardner LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF A PD-1 ANTIBODY AND USE OF THE SAME

Figure 1



(57) Abstract: The present disclosure is provides pharmaceutical compositions, for storage and administration, comprising a human PD-1 ("hPD-1") antibody ("retifanlimab") and buffering agents. The disclosure further provides containers and kits comprising such pharmaceutical compositions. The disclosure further provides the use of such pharmaceutical compositions, containers, and kits containing retifanlimab in the treatment of a cancer, and in certain aspects treatment of a cancer expressing PD-L1.

WO 2023/283049 A1

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*